Jack Padovano: Got it. And then if I could just ask one more on Qelbree. Do you have a granular breakdown of where those prescriptions are coming from in terms of naive patients versus switches from stimulants or non-stimulants? And now with the increasing volumes that you’re getting are payers becoming more permissive with prescribing or are they still requiring step edits?
Tim Dec: Yeah, regarding the source of the business on Calgary, it really cuts in so many different ways. But basically about 29% of the business is from new patients. And the remaining 71%, it’s switching patients from existing medications or adding Calgary to the existing medication. And when you look at the switches themselves, 65% of the switching is coming from the stimulants, and 35% of the switching is coming from non-stimulants. And that is actually a very, very encouraging fact. In looking at the source of the business, we are actually drawing a lot of patients from the stimulant side. A lot of it is due to the AEs that people side AEs mainly as one of the major driver and actually behind it. And of course, in kids or pediatrics, it’s also the parents not willing to put their kids on controlled substances on top of all that.
So, we are very encouraged by this trend and it continues to be that way even from the time we started launching the product in peas and in adults. And then as far as the payers and the step edit and so forth, I mean, it’s a really mixed bag. The first PVM contract we had, it’s actually tier two preferred, so there is no step through. The second one has a minor step through. But again, if you think about the market, let’s say 90% of it is stimulants. So, if you have to go through a stimulant, that’s really not much of an issue. If you have to go through a non-stimulant, it might just delay your initiation on Calgary by three weeks, four weeks or whatever, until when you are dissatisfied with the first non-stimulant clearly. So, it is a mixed bag of different plans, different formularies, different step-throughs or Pas, and so forth.
And we can back to my previous answer on the previous question that is some of the things that we continue to work on and to keep to improve on the coverage and minimize this step-thoroughwort different medications patients have to go through before getting Calgary.
Jack Padovano: Very, helpful. Thank you.
Operator: Seeing no further questions, I would now like to turn it back to Jack Khattar for closing comments.
Jack Khattar : In concluding our call this afternoon, I would like to emphasize that returning to strong growth is our top priority. We are very pleased with our performance in the first quarter, despite the significant erosion of Trokendi XR due to the entry of generics and the typical insurance headwinds. We are confident that our growth products will allow us to offset the impact coming from the loss of exclusivity of Trokendi XR, and to return to revenue and operating income growth in 2024 and beyond. Thanks so much for joining us this afternoon. We look forward to updating you on our next call.
Operator: All right. Thank you for your participation in today’s conference. This does conclude the program. You may now disconnect.
